Cochlear Bone Anchored Solutions AB (“Cochlear”) owns U.S. Patent No. 7,043,040 (“the ‘040 patent”), directed to a hearing aid for use in those with unilateral hearing loss. Oticon Medical AB, etc. (“Oticon”) successfully petitioned for inter partes review (IPR) of all claims of the ‘040 patent, and in those reviews the USPTO Patent and Trial Appeal Board (“PTAB” or “Board”) held claims 4-6 and 11-12 unpatentable, but maintained the validity of claims 7-10. Cochlear appealed the PTAB’s decision with respect to claims 4-6 and 11-12, while Oticon cross-appealed the PTAB’s determination in connection with claims 7-10. The Federal Circuit (Newman, O’Malley and Taranto) affirmed, but for claim 10, on which they vacated and remanded to the PTAB for further action.
Litigation
- CAFC Finds Claim for Delivery Notification System Abstract as Directed to a Longstanding Commercial Practice
- Non-Limiting Preamble Costs Cochlear at CAFC
- Federal Circuit Issues Several Rulings Defining Contours of Arthrex Decision
- (Not) Copyright Infringement: Is dbrand Infringing Nintendo’s IP?
- Supreme Court Reverses Second Circuit Approach to Defense Preclusion in Win for Lucky Brand
Recent Posts
- Defensive Publications: A Cost-Effective Tool to Supplement Your Patent Strategy
- A Stylized Word Mark in One Country May Be Too Simple and Common in Another
- Other Barks & Bites for Friday, May 22: Copyright Office Issues Section 512 Safe Harbor Report, CAFC Denies Review of PTAB Institution Decision and Director Iancu on Possible Filing Deadline Extension
- CAFC Finds Claim for Delivery Notification System Abstract as Directed to a Longstanding Commercial Practice
- PTAB Institution Data Analysis Proves That Reforms Have Failed